Having trouble accessing articles? Reset your cache.

Kintai reveals preclinical validation for its microbiome-inspired small molecules, prioritizes obesity

Led by CEO Tak, Flagship Pioneering’s Kintai adds preclinical validation to its platform with obesity data

The first set of preclinical data from Kintai’s microbiome-derived small molecule platform supports the idea that manipulating the enteric signaling network with small molecules is one way to tap into the microbiome’s

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers